scholarly journals Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Robert Mechera ◽  
Savas D. Soysal ◽  
Salvatore Piscuoglio ◽  
Charlotte K. Y. Ng ◽  
Jasmin Zeindler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oestrogen Receptor ◽  
Prognostic Significance ◽  
Receptor Expression

Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expression

2009 ◽  
pp. n/a-n/a ◽  
Author(s):  
Areeg Faggad ◽  
Jan Budczies ◽  
Oleg Tchernitsa ◽  
Silvia Darb-Esfahani ◽  
Jalid Sehouli ◽  
...  
Keyword(s):  
Oestrogen Receptor ◽  
Prognostic Significance ◽  
Receptor Expression ◽  
Dicer Expression

scholarly journals Methylation of the NT5E Gene Is Associated with Poor Prognostic Factors in Breast Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 939
Author(s):  
Young Ju Jeong ◽  
Hoon Kyu Oh ◽  
Hye Ryeon Choi ◽  
Sung Hwan Park
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Methylation Status ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Receptor Expression ◽  
Gene Methylation ◽  
Clinicopathologic Characteristics ◽  
Large Tumor ◽  
The Mean

Cluster of differentiation (CD) 73, which is encoded by the NT5E gene, regulates production of immunosuppressive adenosine and is an emerging checkpoint in cancer immunotherapy. Despite the significance of CD73 in immuno-oncology, the roles of the NT5E gene methylation in breast cancer have not been well-defined yet. Therefore, we aimed to investigate the prognostic significance of the NT5E gene methylation in breast cancer. The DNA methylation status of the NT5E gene was analyzed using pyrosequencing in breast cancer tissues. In addition, the levels of inflammatory markers and lymphocyte infiltration were evaluated. The mean methylation level of the NT5E gene was significantly higher in breast cancer than in normal breast tissues. In the analysis of relevance with clinicopathologic characteristics, the mean methylation levels of the NT5E gene were significantly higher in patients with large tumor size, high histologic grade, negative estrogen receptor expression, negative Bcl-2 expression, and premenopausal women. There was no difference in disease-free survival according to the methylation status of the NT5E gene. We found that the NT5E gene methylation was related to breast cancer development and associated with poor prognostic factors in breast cancer. Our results suggest that the NT5E gene methylation has potential as an epigenetic biomarker in breast cancer.

scholarly journals Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer

2009 ◽  
Vol 175 (1) ◽  
pp. 334-341 ◽  
Author(s):  
Janna Paulsson ◽  
Tobias Sjöblom ◽  
Patrick Micke ◽  
Fredrik Pontén ◽  
Göran Landberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Human Breast Cancer ◽  
Prognostic Significance ◽  
Receptor Expression ◽  
Platelet Derived Growth Factor ◽  
Human Breast ◽  
Β Receptor

scholarly journals EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival

Oncogene ◽  
1998 ◽  
Vol 17 (8) ◽  
pp. 1053-1059 ◽  
Author(s):  
Rina Hui ◽  
Jonathon R Ball ◽  
R Douglas Macmillan ◽  
Frances S Kenny ◽  
Owen WJ Prall ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cyclin D1 ◽  
Primary Breast Cancer ◽  
Oestrogen Receptor ◽  
Patient Survival ◽  
Receptor Expression

scholarly journals The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer

2014 ◽  
Vol 110 (7) ◽  
pp. 1744-1747 ◽  
Author(s):  
C L Downey ◽  
S A Simpkins ◽  
J White ◽  
D L Holliday ◽  
J L Jones ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oestrogen Receptor ◽  
Prognostic Significance ◽  
Tumour Stroma ◽  
Positive Breast Cancer

scholarly journals Relationship of ER, PR, HER2 / neu with Other Prognostic Factors in Breast Cancer along with the Role of Androgen Receptor in Triple Negative Breast Cancer

2021 ◽  
Vol 10 (8) ◽  
pp. 536-540
Author(s):  
Arshi Khan ◽  
Reeni Malik ◽  
Pramila Jain ◽  
Deepshikha Verma ◽  
Vedanti Newasker
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Oestrogen Receptor ◽  
Triple Negative ◽  
Receptor Expression ◽  
Proliferation Index ◽  
Lymph Node Status ◽  
Significant Information

BACKGROUND Understanding various risk factors associated with breast cancer can help in early identification & prompt treatment of patients with breast cancer. Apart from clinical parameters like age, disease presentation and menopausal status, important prognostic indicators in histopathology are size and extent of tumour, histologic type,histologic grade and lymph node status. Also, there are other factors which are not only predictive of outcome, but also direct therapies against particular molecular targets. These factors are oestrogen receptor (ER) status, progesterone receptor (PR) status, HER2 / neu status, Ki-67 proliferation index & androgen receptor (AR) status. We wanted to analyse various hormone receptors & their correlation with prognostic factors. In addition, androgen receptor expression is also studied in triple negative breast cancer cases. METHODS The study included 50 cases over a period of 18 months from January 2018 to June 2019 received in the Department of Pathology, Gandhi Medical College, Bhopal, India. These cases were subjected to histopathological & immunohistochemistry (IHC) evaluation. RESULTS Among the 50 cases studied, the most common subtype was infiltrating ductal carcinoma (NOS - no special type, 84 %). Majority of patients were ER, PR, HER2 / neu negative (48 %) and among those triple negative cases, 25 % of cases were androgen receptor positive. CONCLUSIONS Expression of the hormone receptor (ER and PR) and HER2 status may provide significant information in directing patient management. Since traditional pathological methods and IHC remain standard for guiding the use of treatment, clinicians may be challenged with equivocal results that directs towards additional testing for definitive diagnosis and, better patient outcome. The most used therapy for advanced breast cancers is based on the use of AR antagonists, such as bicalutamide and enzalutamide, first- and second-generation AR antagonists respectively. Gene signatures, bioinformatics, and other clinical trials are also beneficial for clinician in estimating the benefits expected from adjuvant chemotherapy. KEY WORDS Breast Cancer, Oestrogen Receptor, Androgen Receptor, Triple Negative

Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 536-536 ◽  
Author(s):  
J. Robertson ◽  
E. Gutteridge ◽  
K. L. Cheung ◽  
S. Pinder ◽  
A. Wakeling
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Oestrogen Receptor ◽  
Receptor Expression ◽  
Human Breast
Sign in / Sign up

Export Citation Format

Share Document